Major tasks for Carl Gordon of OrbiMed, a healthcare fund, include drug pricing and helping to turn promising ideas into reality, as he tells LSIPR.
One of the challenges facing healthcare venture capital firms is the pressure concerning drug pricing.
“We need companies to be able to charge a reasonable amount of money for the drugs because, if they can’t, we can’t make returns,” says Carl Gordon, founding partner and co-head of global private equity at OrbiMed.
“It’s easy to criticise pharmaceutical companies for charging a lot for their drugs, so that’s one issue we have to deal with,” he adds.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
LSIPR 50 2017, venture capital firms, drug pricing, pharmaceutical companies, OrbiMed, Johnson & Johnson, AstraZeneca,pharmaceutical